Octreotide for acromegaly treatment: a reappraisal

Abstract

Introduction: Acromegaly is a rare disorder characterized by excess secretion of growth hormone (GH) generally caused by a pituitary macroadenoma and associated with reduced life expectancy if the disease is untreated. This article covers the recent available evidences published on octreotide, the first somatostatin analog introduced into clinical practice for the medical treatment of acromegaly.

Areas covered: This article discusses i) pharmacology of somatostatin and octreotide; ii) biochemical effects of regular octreotide and long-acting repeatable formulation; iii) tumor shrinkage effects of octreotide in acromegaly; iv) impact of octreotide on acromegalic clinical manifestations and chronic complications; v) safety of octreotide and vi) place of octreotide in the guidelines for acromegaly treatment. Full-text articles in the English language were selected from a PubMed search spanning 1984 – 2013, for keywords including ‘octreotide,' ‘acromegaly,' ‘GH,' ‘IGF-I,' and ‘tumor shrinkage.' Reference lists in selected papers were also used to broaden the search.

Expert opinion: Octreotide is a mature drug with a consolidated favorable benefit versus risks profile in the treatment of acromegaly.

Keywords::

• acromegaly treatment
• biochemical control
• octreotide
• shrinkage
• somatostatin analogs

Notes